KTTA - Pasithea Therapeutics Corp

https://www.pasithea.com

Recent News

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Pasithea Therapeutics ( NASDAQ:KTTA )

Benzinga • 4 months, 1 week ago • score: 0.05

PAS-004 showed up to 91% inhibition of pERK at 8mg, indicating strong MEK inhibitor activity. One patient saw a -9.8% tumor shrinkage over 5 months despite prior failed treatments. Don't miss this list of 10 overlooked stocks-including one paying a 9% dividend-before Wall Street catches on.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.

52W High

$7.50

52W Low

$0.65

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.28

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

2.90

EV/Revenue (<3 favorable)

277.44

P/S (TTM) (<3 favorable)

42.15

P/B (<3 favorable)

0.39

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

3.26%

Institutions (25–75% balanced)

10.95%

Shares Outstanding

7,443,600

Float

7,331,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

486,560

Gross Profit (TTM)

-2,213

EPS (TTM)

-7.13

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.86%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

14.98

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—